Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2281MR)

This product GTTS-WQ2281MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2281MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13296MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ12985MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ908MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ10960MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ4732MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ11318MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-524
GTTS-WQ4982MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ8608MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuM195
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW